ACET logo

ACET Adicet Bio, Inc.

NASDAQ Global Market · Biotechnology · Healthcare

$2.14
-0.32 (-13.01%)

Adicet Bio, Inc. is a biotechnology firm dedicated to pioneering allogeneic gamma delta T cell therapies, aiming to treat cancer and various other diseases. The company’s strategy involves engineering gamma delta T cells with chimeric antigen receptors (CARs) and T cell receptor-like antibodies. This advanced modification is designed to achieve more precise targeting of tumors, enhance the body's …

Market Cap: $20.03Mwww.adicetbio.com

Price

No data yet.

Social Signal Score

50
5d
—
30d
—
60d
50
2 mentions
—
90d
50
3 mentions
—
news: 3

Analyst Ratings

12 analysts
Buyconsensus
Strong Buy 0Buy 9Hold 3Sell 0Strong Sell 0
Avg price target$27+1161.7%
Low $27Median $27High $27
Current Consensus

Revenue

$0.00-100.00%
$-430.51M$-223.63M$-16.75M$190.13M
Dec 2016Sep 2026

Analyst Estimates

FY2025
$-16.17
$-16.17–$-16.17
3 analysts
FY2026
$-7.26
$-7.33–$-7.19
4 analysts
FY2027
$-4.95
$-6.71–$-3.18
4 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Chen Schor
Sector
Healthcare
Industry
Biotechnology
Employees
102
Beta
1.69
Country
US
Piotroski score
2 / 9 (Weak)
Altman Z-score
-8.39
www.adicetbio.com